Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer

29Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Gastric cancer is a prevalent tumor that is usually detected at an advanced metastatic stage. Currently, standard therapies are mostly ineffective. Here, we report that Glypican-3 (GPC3) is absent in invasive tumors and metastatic lymph nodes, in particular in aggressive and highly disseminated signet ring cell carcinomas. We demonstrate that loss of GPC3 correlates with poor overall survival in patients. Moreover, we show that absence of GPC3 causes up-regulation of MAPK/FoxM1 signaling and that blockade of this pathway alters cellular invasion. An inverse correlation between GPC3 and FoxM1 is also shown in patient samples. These data identify GPC3 as a potential metastasis suppressor gene and suggest its value as a prognostic marker in gastric cancer. Development of therapies targeting signaling downstream of GPC3 are warranted.

Cite

CITATION STYLE

APA

Han, S., Ma, X., Zhao, Y., Zhao, H., Batista, A., Zhou, S., … Zhang, Z. (2016). Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer. Oncotarget, 7(28), 44406–44416. https://doi.org/10.18632/oncotarget.9763

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free